A recent symposium inaugurating the department of systems biology at Columbia University Medical Center comes at a very auspicious time, one in which biomedical sciences, chemistry, physics, engineering, bioinformatics, and computer sciences are converging to shape a vibrant new discipline.
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As Lee Goldman, M.D., M.P.H., executive vice president for health and biomedical sciences at the Columbia University College of Physicians and Surgeons pointed out during the opening remarks, this new feld "represents so much about our future."
Within a relatively short time, we have realized the possibility of sequencing and mapping the genome of virtually any organism. Concomitantly, as increasingly sophisticated technologies allow whole-genome sequences to be completed within hours to days, navigating the vast datasets has become the foremost challenge, opening a gap in our ability to understand and interpret their signifcance.
"While elucidating the genome has given us a tremendous amount of information, it has revealed very little about how those parts work together," says Andrea Califano, Ph.D., professor and chair of the department of systems biology at Columbia. At the recent systems biology inaugural symposium, several investigators affliated with the department unveiled research programs and interdisciplinary approaches that promise to integrate a plethora of knowledge on cellular and molecular processes into cross-disciplinary frameworks.
Protein-Protein Interactions
"We wanted to put a structural face on protein-protein interactions that occur in cells over time," said Barry Honig, Ph.D., professor of biochemistry and molecular biophysics. In parallel with emerging knowledge about the cellular ensemble of protein-protein interactions, the possibility of using structural information to describe protein-protein interfaces on a large scale has attracted increasing attention. "But there are challenges associated with this, and the main challenge is the existence of many more genes than structures," Dr. Honig added.
Thousands of human proteins have at least one known domain structure, yet only approximately 500 protein-protein complex structures are available in the protein data bank. At the same time, approximately 80,000 interactions are described in publicly available databases, and many more are anticipated to occur in cells. "What we want to do is mine structural information about those interactions," explained Dr. Honig.
One of the key approaches used by Dr.
Honig and colleagues, homology modeling, takes advantage of the possibility of fnding, given a query sequence of unknown structure, another sequence that is related through alignment and whose structure is known. Models of proteins or protein fragments can be analyzed by three-dimensional superimposition, in an approach that Dr. Honig coined as structural BLAST. Building on this strategy, Dr. Honig and colleagues developed and validated an algorithm known as PrePPI (predicting proteinprotein interactions), and used it to generate a database of over 300,000 predictions for protein interaction pairs. PrePPI is based on Bayesian statistics and relies on the input of structural and nonstructural information.
For a pair of query proteins thought to interact, structures for subunits from each protein are obtained from databases or are generated by homology modeling. After fnding structural neighbors for each subunit, a template is identifed for a pair of structural neighboring chains, and a model is built by superimposing individual subunits on their "Science is more than a body of knowledge, it's a way of thinking," remarked Carl Sagan, and probably his words were never more powerfully relevant than for portraying one of the newest biomedical felds, systems biology. 
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NEWS Molecular Diagnostics
> Federal Court Invalidates Sequenom-Licensed Patent for Diagnostic Test
A federal court invalidated a Sequenom-licensed patent covering the detection of fetal cell-free DNA in the bloodstream of pregnant women, upholding a challenge from Ariosa Diagnostics.
Judge Susan Illston of the U.S. District Court for the Northern District of California issued a summary judgment in favor of Ariosa, declaring that U.S. Patent No. 6,258,540 covered patent-ineligible subject matter-namely the presence of fetal DNA in the mother's blood, which the judge said fell into the natural-phenomenon exemption from patentability under Section 101 of the U.S. Patent Code. Judge Illston added that claims covering detection of that DNA were unpatentable because they involved conventional genetic techniques.
Sequenom had been using the patent to protect its MaterniT21 Plus noninvasive prenatal diagnostic test, which poses a lower risk of miscarriage than older techniques such as amniocentesis or chorionic villus sampling. Ariosa, formerly Aria Diagnostics, sued Sequenom in December 2011, seeking a declaratory judgment that its Harmony™ Prenatal Test did not infringe the patent.
> Transgenomic, PerkinElmer to Co-Market Oncology Diagnostics
Transgenomic has entered an agreement with PerkinElmer to market and distribute its oncology diagnostic test portfolio of products.
PerkinElmer will have the nonexclusive right to begin sales, marketing, distribution, and feld service activities in territories outside the United States for Transgenomic's line of molecular diagnostic oncology products, including CRC RAScan™ and ACE™ kits, for use on PerkinElmer's LabChip MultiDx platform. The collaboration will be efective at the start of next year and initially launch in Europe.
The CRC RAScan provides a single-kit solution for detecting KRAS and NRAS genetic mutations that are relevant when considering administration of select EGFR inhibitor therapies associated with metastatic colorectal cancer, according to Transgenomic. The companies will offer testing solutions that include DNA extraction, oncology diagnostic assays, and high-performance microfuidics instrumentation.
> Ventana, Incyte Partner on Companion Diagnostics
Ventana Medical Systems, a member of the Roche Group, has entered into an agreement with Incyte to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program. As part of the agreement, Ventana will support Incyte's personalized medicine healthcare strategies for cancer drug development using its expertise in companion diagnostics and immunohistochemistry technology platforms, as well as its worldwide customer support network.
n The homodimer of the ligand binding domain of the nuclear hormone receptor, LXR, is used to predict an interaction between another hormone receptor, PPARg, and the homeodomain of PAX7. One subunit of the LXR homodimer is shown in red and the other in blue. A structure of the ligand binding domain of PPARg, shown in green, is superimposed on the blue subunit, and a homology model of the homeodomain of PAX7 is shown in yellow, superimposed on the other. A single structure-derived score, combined from fve different structure-based scores, generated to evaluate the model, refects the likelihood that the interaction represents a true complex. Nonstructural information, such as functional and evolutionary similarities, is subsequently incorporated into the model. "This could not have been possible without applying systems biology thinking to structural biology," said Dr. Honig.
Perturbations and Pathways
"I was fascinated by processes that have evolved to create such amazingly precise spatiotemporal gene expression patterns, and I was even more astounded to realize that information underlying these patterns is encoded in the sequence," explained Saeed Tavazoie, Ph.D., professor of biochemistry and molecular biophysics. A major effort in Dr. Tavazoie's lab has focused on the concept of predicting gene expression dynamics from information encoded in the sequence.
Decades ago, Dr. Tavazoie's approach would have been diffcult to implement. However, the advent of microarray technology, which allows the expression of thousands of genes to be surveyed simultaneously under a broad range of conditions, has been instrumental toward making this approach become reality.
Previously, Dr. Tavazoie and colleagues developed a computational pipeline to profle a number of gene expression perturbations occurring in a large number of different cellular states, and the genes were subsequently clustered into co-expression modules. "We then looked at the regulatory regions for the occurrence of de novo motifs that are enriched in these genes with regard to the background of the genome," said Dr. Tavazoie.
These motifs were predicted to function as transcriptional regulator binding sites, and the strategy provided a powerful approach to perform reverse engineering in simple organisms. "However, going from yeast to humans has been more challenging, due to the scale and the complexity of the human genome," reported Dr. Tavazoie.
To address this challenge, Dr. Tavazoie's lab developed new algorithms based on information theory that enable sensitive and specifc detection of transcriptional and posttranscriptional regulatory elements within the human genome. In particular, TEISER (Tool for Eliciting Informative Structural Elements in RNA) is a new framework that enables the discovery of structural RNA elements by using context-free grammars and mutual information. "The application of TEISER to mammalian datasets is revealing a rich picture of mRNA stability regulation by these elements and the RNA-binding proteins that bind them," said Dr. Tavazoie.
In a recent genome-wide, systems-level analysis of 46 different cancers, Dr. Tavazoie and colleagues used cancer gene expression datasets to identify known pathways and processes that are perturbed. "We have identifed some of the most commonly recurring elements in several cancers, and this allowed us to dig deeper into individual functional categories and pathways, such as those involved in regulating apoptosis or the mitotic cell cycle," Dr. Tavazoie added.
Quantitative gene expression measurements and pathway analyses on these data also allowed causality between perturbations and the pathways that are changed to be explored. This approach revealed that, as opposed to a "universal" signature for tumor pathways, perturbed pathways are very diverse, and cellular modifcations underlying the malignant state are broadly heterogeneous.
Additionally, the systematic analysis of cis-regulatory elements showed that only approximately 25% of the newly discovered motifs corresponded to known binding sites, illustrating the complexity of the malignant state and the limited amount of information that we currently have on describing cellular perturbations that characterize it.
Co-opting Biological Systems
"We developed the ability to synthesize almost any molecule that we would like to, but one great challenge for the feld is transitioning from individual molecules to networks that function together inside the living cells," explained Virginia W. Cornish, Ph.D., professor of chemistry.
As part of early efforts to co-opt directed evolution to build new molecules inside cells, Dr. Cornish and colleagues linked the chemistry of enzyme catalysis to cell survival. "We envisioned that we could do this by including small molecule chemistry into the yeast two-hybrid assay. This involves selecting for enzymes that catalyze the synthesis or the cleavage of a bond based on the transcription of an essential reporter gene and coupling two small molecules," Dr. Cornish said.
This concept, which initially took advantage of the high-affnity interaction between methotrexate and dihydrofolate reductase, provided the possibility of exploiting orthogonal chemistry in a robust way inside living cells, and is currently being widely used for many applications, such as assays for controlled protein degradation.
The proof of principle for linking enzyme catalysis to reporter genes exploited cephalosporin hydrolysis by the Enterobacter cloacae P99 cephalosporinase, which was incorporated into a three-hybrid system to measure cephalosporinase activity in vivo as a change in lacZ transcription, and this screen also helped isolate wild-type cephalosporinase from a pool of inactive mutants.
The Translational Medicine emerged as an attractive experimental possibility. "As we started taking advantage of the budding yeast as an organism in which to study directed evolution, we sought ways to perform mutagenesis in this setting," said Dr. Cornish. While Dr. Cornish and colleagues initially exploited homologous recombination as a mutagenesis strategy, they saw the dependence on transformation emerge as a shortcoming. "We addressed this by placing the DNA on a heritable cassette plasmid, embedding it in endonuclease sites, and performing endonuclease cleavage to create double-stranded breaks and recruit the homologous recombination machinery, and this helped generate reasonably large libraries," Dr. Cornish explained.
Synthetic and systems biology promise to profoundly impact the feld of biosynthetic engineering. "Increasingly, rather than make drugs by chemical synthesis, we can engineer yeast and other organisms to biosynthesize intermediates on which we can do further chemistry," he continued.
In a current project, Dr. Cornish and colleagues are using engineered yeast as a lowtech biosensor for cholera. Receptors that recognize cholera were engineered on the surface of yeast, and the yeast were engineered to turn on a plant pigment. "We can, in this way, envision a very cheap and safe product that we can hand out into local communities for the detection of cholera by nontechnical people in the community," Dr. Cornish added.
Single-Cell Analysis
"When we take a complex tissue and perform expression profling, we do not necessarily know the cellular origin of the molecules that were quantifed," says assistant professor Peter A. Sims, Ph.D. In cellular populations, biological processes are unlikely to occur in a synchronous fashion, and this opens signifcant challenges for analyzing those processes and interpreting the data.
One approach to address this shortcoming is to perform analyses at the single-cell level. "We wanted to look at the transcriptomes of individual cells," explained Dr. Sims. Examining many genes across large numbers of individual cells provides an ideal way to catch a glimpse of biological processes at the singlecell level, and concomitantly capture interindividual heterogeneity in the population.
Ideally, single-cell analysis should be performed by direct detection, to avoid the consequences of amplifcation bias, and the approach should be time-effcient and affordable. "At this time, we do not have a technology that does not compromise the number of cells analyzed in favor of the number of targets analyzed and vice versa, so it is very diffcult to look at a lot of genes and a lot of cells with one tool," said Dr. Sims.
Investigators in Dr. Sims' lab rely on two approaches for single-cell analysis, microfuidics and microscopy. Microfuidics uses very small reagent volumes and consequently reduces contamination, whereas microscopy provides additional visual information about the system being examined at a specifc time.
By using soft lithography microfuidics, a technology that allows single-cell behavior to be captured under a broad number of conditions, Dr. Sims and colleagues have developed tools for single-cell transcriptome analysis. One of these tools, targeted probebased expression profling, offers the possibility of simultaneously exploring several tens of genes within the same cell. "The advantage of this approach is that we are able to probe the transcriptome at the location where the cell is observed," noted Dr. Sims.
With each cell in its own picoliter-sized chamber, the array can be sealed with a glass surface that is chemically functionalized to allow the capturing of the RNA, which can be reverse transcribed. "We are also developing another tool that uses microarray platforms for largescale, genome-wide RNA sequencing, where we can generate thousands of cDNA libraries on the microarray well chip," Dr. Sims said. Systems biology has made it possible to test hypotheses that merely a few years ago were beyond the reach of experimental approaches. Nonetheless, by working at the juncture of biomedicine, biotechnology, and the clinic, scientists are extending their reach, unveiling mechanistic details, and hastening paradigm shifts. Central to these endeavors, and one of the fundamental teachings that has emerged thus far, is the power of science's integrative nature.
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Translational Medicine
Interaction between antigen-specifi c T cells and antigen presenting cells (APC) cognate ligand involve reorganization of the cytoskeleton and recruitment of adhesive and signaling molecules to the site of intercellular contact. Sustained adhesion of T cells to APCs and formation of the immunological synapse after T cell receptor stimulation are required for the antigen-specifi c response. One way to measure an immunological synapse is by fl uorescently labeling the molecules that have been recruited to the synapse and imaging via confocal or conventional fl uorescence microscopy. However, immunological synapses are often rare and therefore diffi cult to analyze objectively and statistically by traditional microscopy methods. In this study, the Amnis ® FlowSight ® imaging fl ow cytometry platform was employed to collect imagery of large numbers of cells to assess the percentage of T cells involved in an organized immunological synapse.
Quantifying the frequency of organized immunological synapse
In this experiment, Raji B cells were loaded with Staphylococcal enterotoxin B (SEB) to make APCs.
ADVERTORIAL
Cytometry without limits
Extend the Range of Your Research
The Amnis ® FlowSight ® and ImageStream X Mark II cytometers combine the speed, sensitivity, and phenotyping abilities of fl ow cytometry with the detailed imagery and functional insights of microscopy. This unique combination enables a broad range of applications that would be impossible using either technique alone.
The FlowSight cytometer provides up to 4 lasers and 12 images of every cell for visual verifi cation and quantitative image analysis. The ImageStream X Mark II delivers high-resolution imagery at up to 60X magnifi cation for more demanding applications, as well as additional lasers, options, and capabilities. Step 1: Plot the Aspect Ratio vs Area of the brightfi eld image to identify doublets. Step 2: Find cells that are positive for both CD3 (orange) and CD19 (green). Step 4: Plot the Aspect Ratio vs Area of the CD3 signal from the doublets with only one CD19+ cell to isolate doubles with only one CD3+ cell.
This fi nal population consists of doublets with only one CD19+ Raji B cell and one CD3+ T cell. Step 3: Plot Aspect Ratio vs Area of the CD19 signal from the double positive population to isolate doublets with only one CD19+ cell.
"We are focusing on bacterial and human systems, and we are beginning to study the interface of the two, the microbiome, from a synthetic biology perspective, " says James J. Collins, Ph.D., professor of biomedical engineering at Boston University. Dr. Collins served as keynote speaker at Columbia's recent symposium. Many advances in systems and synthetic biology have become reality thanks to landmark developments, and one of these was the construction of transcriptional switches that co-opted RNA regulatory functions. A signifcant stride came in 2004, when Dr. Collins and colleagues reported the development of a post-transcriptional Escherichia coli RNA-based regulator that was able to either suppress or activate gene expression.
In this model, a cis-repressive sequence inserted upstream of a ribosome binding site formed a stem-and-loop structure at the 5'-untranslated region of the mRNA, interfering with gene expression. Also, a small noncoding RNA molecule expressed in trans was able to target the repressed RNA, activating gene expression. Subsequently, Dr. Collins and colleagues developed genetic counters. With this approach, several RNA switches are serially activated by output from the previous switch, allowing user-defned induction transcriptional output events to be counted.
These advances opened the need to generate synthetic circuits that can be programmed to also kill a cell that has been rewired with a new function. By using two lytic proteins, Dr.
Collins' lab developed a programmable kill switch. "After three public hearings, the Presidential Commission for the Study of Bioethical Issues highlighted the kill switch as a muchneeded safeguard, " said Dr. Collins. In addition to safety, this system ofered other advantages. "After we published this work, several biotech companies showed interest in using this technology for combating corporate espionage, " explained Dr. Collins. They feared that competitors could obtain engineered microbial strains. This concern is alleviated if a microorganism is endowed with the property to self-destruct when programmed to do so.
"What really has been driving my lab is going after antibiotics, " remarked Dr. Collins. The need to develop new antimicrobial agents, or to devise new approaches to address antimicrobial resistance, is fueled by the increasing number of resistant strains, a trend that is compounded by the decreasing number of newly developed and approved antimicrobial agents.
"We collected hundreds of E. coli expression profles, and used systems biology to develop whole-scale genome models to gain new insights into how antibiotics work, " said Dr. Collins. Experiments on quinolones revealed that the DNA damage response network was a key participant in bacterial response. The oxidative damage response network was also induced, however, and studies on additional antibiotics revealed that they can also alter cellular metabolism and afect cellular respiration as part of their mechanisms to cause bacterial cell death.
"We tried to use these fndings to boost the killing efcacy of antibiotics, " added Dr. Collins. In a high-throughput assay that examined over 2,000 compounds, Dr. Collins and colleagues showed that the bactericidal activity of antibiotics was improved with RecA inhibitors. Subsequently, the use of bacteriophages overexpressing LexA3, a noncleavable version of the SOS system repressor LexA, boosted from 100-to 10,000-fold the in vitro killing efcacy of bactericidal antibiotics, and illustrated the possibility of using engineered bacteriophages as antibacterial adjuvants.
Moreover, in the frst animal study in systems biology, the antibiotic-enhanced bacteriophage in combination with quinolone treatment rescued 80% of the mice from death. "Much of what is happening in synthetic biology is still at the microbial stage, and we would like to move this feld toward higher organisms, " concluded Dr. Collins. The SEB-loaded APCs were incubated with human T cells purifi ed from peripheral blood. After incubation the cells were fi xed, permeabilized and labeled with CD3-PE-Texas Red (T cells, orange), CD19-AF488 (Raji B cells, green), phalloidin-AF647 (actin, red) and DAPI (nuclear stain, purple).
A FlowSight imaging fl ow cytometer equipped with the Quantitative Imaging (QI) option was used to assess the frequency of conjugates with an organized immunological synapse. Image analysis was completed using image-based algorithms available in the IDEAS 5.0 image analysis software package. Figure 1 demonstrates how to isolate cell conjugates using the IDEAS software.
Polymerization and concentration of actin at the immunological synapse results in a high local pixel intensity. A "Valley" mask operation on the DAPI image defi ned the region of contact between cell conjugates, as shown in Figure 2 . The actin intensity was then quantifi ed within the Valley mask.
In addition, the overlap between the cells was measured by using the Co-localization wizard in the IDEAS 5.0 software. The Co-localization wizard measures the Bright Detail Similarity between two images (the cross-correlation of the smaller fl uorescence features), in this case CD3 and CD19. Higher Bright Detail Similarity scores are associated with greater overlap between the cells and an organized immunological synapse.
By plotting the Bright Detail Intensity of the actin in the Valley mask vs the Bright Detail Similarity of the CD3 and CD19, the number of cells with an organized immunological synapse were quantifi ed, as shown in Figure 3 . The percent of T cells in the Immune Synapse gate was 8.4% for the SEB-treated sample versus 1.6% for the control (no SEB) sample.
Conclusion
Imaging fl ow cytometry combines the quantitative power of large sample sizes common to fl ow cytometry with the information content of microscopy. This study utilized the FlowSight and its companion IDEAS data analysis software to demonstrate in an objective and statistically robust manner that there is a signifi cant increase in number of cell conjugates with an organized immunological synapse when the APCs have been loaded with SEB. A team led by Boston University's Dr. James Collins collected numerous E. coli expression profles and then used systems biology to develop wholescale genome models to gain novel insights on how antibiotics work.
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